#Israel #Medtronic #Restore Medical #Chris Cleary #Or-Yehuda

Restore Medical Welcomes Chris Cleary as Chairman of the Board

Restore Medical Ltd., a pioneering company in developing innovative medical devices, is thrilled to announce the appointment of Chris Cleary as the new Chairman of its Board of Directors. This significant decision comes as the company readies itself to expand its clinical trials and aim for advanced studies in the U.S. for its groundbreaking transcatheter therapy specifically designed for patients suffering from heart failure with reduced ejection fraction (HFrEF).

Advancing Medical Innovations

Restore Medical has been at the forefront of addressing heart failure, a condition that impacts millions globally. The company is focused on creating a minimally invasive solution that promises to enhance cardiac function in patients with HFrEF. With positive initial clinical feedback, the organization is now gearing up for the next phase of its clinical program, emphasizing the need for skilled leadership to drive its goals. Chris Cleary’s extensive experience in the healthcare sector positions him as an ideal leader for this endeavor.

Chris Cleary, who previously served as the Senior Vice President of Corporate Development at Medtronic, brings over 30 years of expertise in medical technology and healthcare. His track record includes spearheading high-profile transactions and partnerships in the med-tech landscape, notably Medtronic's monumental $50 billion acquisition of Covidien.

A Vision for the Future

Gilad Marom, CEO of Restore Medical, expressed his enthusiasm regarding Cleary's appointment. He stated, "Chris has been pivotal in forming essential strategic alliances in medical technology. His wealth of experience and strategic insights will be crucial as Restore Medical embarks on expanding its clinical initiatives and prepares for significant studies of its innovative heart failure therapy. We are delighted to have him on our board."

In response to his new role, Cleary conveyed his excitement, highlighting the unique potential of Restore Medical's technology. He said, "This company is addressing a critical gap in heart failure management with a technology poised to redefine patient treatment and significantly improve outcomes. I am eager to support the Restore team in establishing a robust foundation for clinical and commercial success."

Empowering Patients and Healthcare

The mission of Restore Medical is clear: to restore quality of life for countless individuals afflicted by heart failure. The introduction of its proprietary transcatheter therapy aims to deliver a safe and effective minimally invasive solution, carrying the potential to change the therapeutic landscape for heart failure patients significantly.

Restore Medical has garnered support from prominent healthcare investors and boasts partnerships with entities such as Pitango HealthTech and Peregrine Ventures, alongside backing from the European Innovation Council (EIC) Fund. The company is headquartered in Or-Yehuda, Israel, and is poised for growth as it navigates the critical phases of its medical advancements.

Conclusion

With the addition of Chris Cleary to the leadership team, Restore Medical is well-positioned to advance its innovative contributions to heart failure treatment. The company is not only laying the groundwork for clinical success but is also committed to improving the lives of patients worldwide through groundbreaking medical interventions. As they embark on this new era, the future looks promising for both Restore Medical and the many patients who will benefit from their innovations.